Plaquenil Retinal Toxicity: Protecting Your Vision
Understanding Plaquenil Retinal Toxicity
Plaquenil (hydroxychloroquine) is a medication approved for the treatment of rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus in adults. It works by calming an overactive immune system. This helps reduce inflammation, joint pain, and other symptoms of autoimmune disease. Many patients take this medication for years or even decades to keep their condition under control.
When Plaquenil is taken over a long period, it can accumulate in the retina. The drug binds to melanin in the retinal pigment epithelium, or RPE, a layer of cells that supports the photoreceptors responsible for vision. This binding may disrupt several critical functions in the retina. These include retinol (vitamin A) recycling and lysosomal function, which is how cells break down and recycle waste. Over time, this disruption damages both the RPE and the overlying photoreceptors, particularly the macular cones located just outside the fovea (the center of sharpest vision).
One important feature of Plaquenil toxicity is that retinal damage can continue to progress even after the medication is discontinued. This is believed to occur because the drug remains bound to melanin in the RPE for an extended period. The persistent presence of the drug in retinal tissue means that the toxic effects do not stop immediately when a patient stops taking Plaquenil.
Who Is Affected and Risk Factors
The overall prevalence of hydroxychloroquine retinopathy is approximately 7.5% among users (AAO, 2014). At recommended doses, the risk of toxicity is under 1% within the first 5 years and under 2% within the first 10 years. However, the risk rises to nearly 20% after 20 years of use (AAO, 2016). These numbers highlight the importance of ongoing screening for anyone taking the medication long term.
The two strongest risk factors for developing Plaquenil retinal toxicity are the daily dose and the total duration of use. Patients who take more than 5.0 mg per kilogram of actual body weight per day face a significantly higher risk, with an odds ratio of 5.67 (AAO, 2014). Patients who have been on the drug for more than 10 years also have an elevated risk, with an odds ratio of 3.22 (AAO, 2014). Keeping the daily dose at or below 5.0 mg/kg is one of the most effective ways to reduce risk.
Kidney disease is a significant risk factor because the kidneys are responsible for clearing Plaquenil from the body. When kidney function is impaired, the drug can accumulate to higher levels, increasing the chance of retinal damage. The odds ratio for retinal toxicity in patients with kidney disease is 2.08 (AAO, 2014).
Tamoxifen citrate, a medication used to treat breast cancer, increases the risk of Plaquenil retinal toxicity roughly fivefold. The odds ratio for patients taking both tamoxifen and Plaquenil is 4.59 (AAO, 2014). Patients on both medications should be monitored especially closely.
Additional factors that may increase the risk of retinal toxicity include:
- A daily dosage over 400 mg, or over 6.5 mg/kg of ideal body weight in patients of short stature
- A total cumulative dose of more than 1,000 grams over a lifetime (AAO, 2016)
- Pre-existing retinal or macular disease, which may make the retina more vulnerable to further damage
Signs and Symptoms
In the early stages, Plaquenil retinal toxicity usually does not cause noticeable symptoms. This is one of the reasons routine screening is so important. The damage can begin and progress without the patient being aware of any changes in their vision. Modern imaging technology can detect subtle retinal changes before symptoms appear.
As toxicity develops, patients may begin to notice paracentral scotomas (blind spots near the center of vision but not directly in it). These blind spots can cause difficulty with reading, because words or letters may seem to disappear. Some patients may also notice diminished color vision. However, most patients do not become aware of these symptoms until the scotomas have become relatively large and the damage is more advanced.
When retinopathy worsens, central visual acuity and paracentral vision become increasingly affected. Patients may have significant difficulty reading, recognizing faces, or performing tasks that require detailed central vision. In severe cases, the classic finding on examination is called a bull's eye maculopathy, a ring of damaged tissue surrounding the fovea. At this stage, the vision loss is typically substantial and irreversible.
Diagnosis and Testing
All patients should have a comprehensive eye examination within the first year of starting Plaquenil therapy. This baseline exam establishes what the retina looks like before any potential damage has occurred. The examination includes a thorough assessment of risk factors and a detailed fundus examination (a close look at the retina). This helps rule out any pre-existing macular disease that could be confused with drug toxicity later on.
Optical coherence tomography, or OCT, is a noninvasive imaging test that creates highly detailed cross-sectional images of the retina. It can detect thinning or disruption of the outer retinal layers before any changes are visible during a standard eye exam. OCT has become one of the most important tools for detecting early, pre-symptomatic Plaquenil toxicity. Advances in OCT imaging over the past decade have significantly improved the ability to catch damage at its earliest stages.
Automated visual field testing, particularly the Humphrey 10-2 visual field test, is used to detect paracentral scotomas. This test maps the central 10 degrees of vision and can reveal blind spots that the patient may not yet notice. It is one of the primary screening tests recommended by the American Academy of Ophthalmology for patients on long-term Plaquenil therapy.
Multifocal electroretinography, or mfERG, measures the electrical responses of individual areas of the retina to light. It can detect localized areas of reduced retinal function, even when the retina appears normal on imaging. While not available at every practice, mfERG can provide additional confirmation of early toxicity when other test results are borderline or unclear.
Fundus autofluorescence, or FAF, is an imaging technique that reveals the health of the RPE by detecting naturally fluorescent substances in retinal cells. In Plaquenil toxicity, FAF can show patterns of increased or decreased fluorescence that indicate RPE damage. This test is often used alongside OCT and visual field testing to provide a more complete picture of retinal health.
Treatment Options
There is currently no treatment that can reverse or repair retinal damage caused by Plaquenil. Once the photoreceptors and RPE cells are damaged, they do not regenerate. This is the reason that early detection is considered the most critical part of managing Plaquenil toxicity. The goal of all screening efforts is to catch changes before significant, irreversible vision loss has occurred.
When screening tests detect early signs of retinal toxicity, the most important step is to notify the prescribing physician. The medication can then be discontinued or an alternative treatment can be considered. Stopping Plaquenil can slow or halt the progression of retinal damage. However, some progression may continue for a period after discontinuation due to the drug's persistence in retinal tissue. The decision to stop the medication involves weighing the risk of vision loss against the benefits of ongoing autoimmune disease management. This decision should be made collaboratively between the patient, their prescribing physician, and their retina specialist.
Patients who stop Plaquenil due to early signs of toxicity should continue to have regular retinal examinations. Because the drug can remain bound in retinal tissue for an extended period, damage may continue to develop even after the medication has been stopped. Continued monitoring ensures that any progression is documented and that the patient receives appropriate support for any vision changes.
What to Expect
The American Academy of Ophthalmology recommends a baseline eye examination within the first year of starting Plaquenil. After the baseline, annual screening should begin after five years of use for patients at low risk. Patients with additional risk factors, such as kidney disease, high dosage, or tamoxifen use, may need to begin annual screening sooner. A retina specialist can help determine the appropriate screening schedule based on individual risk factors.
A typical screening visit involves a dilated eye examination, OCT imaging, and visual field testing. Some visits may also include fundus autofluorescence or other specialized tests. The entire process is noninvasive and usually takes about one to two hours. The retina specialist will compare current results to previous examinations to look for any new changes in retinal structure or function.
When toxicity is detected at an early stage, before symptoms have developed, stopping the medication can help preserve useful vision. Patients may have only subtle changes on imaging with no noticeable impact on daily activities. However, early detection does not mean that vision will certainly remain stable, as some progression can occur after discontinuation. Regular follow-up remains essential.
When Plaquenil retinal toxicity is detected at a later stage, patients may already have noticeable vision loss. At this point, the damage is more extensive and more likely to affect daily activities such as reading and driving. Stopping the medication is still recommended to limit further progression, but vision that has already been lost cannot be restored. Low vision services and adaptive strategies may be helpful for patients with significant vision impairment.
Living with Plaquenil Retinal Toxicity
Patients who develop vision loss from Plaquenil toxicity can benefit from low vision rehabilitation. A low vision specialist can recommend magnifying devices, lighting adjustments, and other tools to help maintain independence. Many patients find that adapting their environment, such as using large-print materials and high-contrast settings on electronic devices, helps them continue daily activities.
Patients taking Plaquenil should make sure that all of their doctors are aware of the medication and the need for regular eye screening. This includes the prescribing physician, any retina specialist, and any other eye care provider. Open communication between specialists helps ensure that screening happens on schedule and that any changes in risk factors are addressed promptly.
Patients can take several steps to reduce their risk of developing Plaquenil retinal toxicity:
- Follow the prescribed dosage and do not exceed the recommended amount based on body weight
- Attend all scheduled eye screening appointments
- Inform your retina specialist if you have kidney disease or are taking tamoxifen
- Report any new vision changes, such as difficulty reading or blind spots, to your eye care provider promptly
When to See a Retina Specialist
All patients should have a comprehensive eye examination, including evaluation of the macula, before starting Plaquenil or within the first year of use. This baseline exam is essential for detecting any pre-existing retinal conditions. It also establishes a reference point for future comparisons. A retina specialist can provide the detailed evaluation needed for patients who have known macular conditions or other risk factors.
Annual retinal screening is recommended for patients who have been on Plaquenil for more than five years. Patients with higher risk factors should discuss earlier and more frequent screening with their retina specialist. If any screening test shows a change from baseline, the retina specialist will determine whether the findings suggest early toxicity or another condition.
Any new blind spots, difficulty reading, or changes in color vision should be reported to a retina specialist promptly. While these symptoms can have many causes, they are among the warning signs of Plaquenil retinal toxicity. Early evaluation gives the best chance of preserving remaining vision.
Questions and Answers
No. There is currently no treatment that can reverse retinal damage caused by Plaquenil. Once the photoreceptors and retinal pigment epithelium cells are damaged, they do not recover. This is why screening to catch changes early, before significant vision loss occurs, is the most important strategy. Stopping the medication when early signs are detected can help prevent further progression.
The risk of retinal toxicity is very low in the first five years of use at recommended doses, under 1% (AAO, 2016). The risk increases with longer use, rising to nearly 20% after 20 years (AAO, 2016). Baseline screening within the first year and annual screening after five years is recommended for most patients. Those with additional risk factors may need to start screening sooner.
In some cases, retinal damage can continue to progress for a period after the medication is discontinued. This happens because Plaquenil binds to melanin in the retinal pigment epithelium and remains in the tissue even after the drug is stopped. Continued monitoring after discontinuation is important so that any further changes can be tracked and managed appropriately.
No dose completely eliminates the risk, but keeping the daily dose at or below 5.0 mg/kg of actual body weight significantly reduces it. At this dosage, the prevalence of retinal toxicity remains less than 2% within the first 10 years of use (AAO, 2014). Your prescribing physician and retina specialist can work together to determine the lowest effective dose for your condition.
A regular eye exam typically checks vision, eye pressure, and the overall health of the eye. Plaquenil toxicity screening is more specialized and includes tests designed to detect early retinal damage. These tests include optical coherence tomography (OCT), automated visual field testing, and sometimes fundus autofluorescence or multifocal electroretinography. These advanced tests can reveal subtle changes in retinal structure and function that a standard exam might not detect.